Why Trump’s proposed healthcare cuts may go nowhere

President Donald Trump is looking to a rarely-utilized process called “rescission” to cut $15 billion in federal spending he already signed into law earlier this year—with much of the reductions coming from programs like the Centers for Medicare and Medicaid Innovation (CMMI) and the Children’s Health Insurance Program (CHIP).

The cuts would come from the $1.3 trillion omnibus spending bill approved by Congress and signed into law by Trump in March. After outcry from conservative groups about the inclusion of many Democrats’ budget requests, the White House began working on what spending could be clawed back under this “rescission” process. It will require only a simple majority in both the House and Senate, but this would be the largest amount ever rescinded and the first time the process has been used in almost 20 years, according to the Washington Post.

Reductions would largely come from $7 billion in two CHIP accounts: $5 billion in previously authorized funding that went unused and another $2 billion in a contingency fund states could tap into for reimbursement when enrollment is higher than expected. Another $800 million in cuts would impact CMMI.

Trump and conservatives in Congress appeared eager to cut even more from the omnibus spending bill, with the White House saying this is “one of several upcoming rescissions packages.”

“After that last spending bill, we owe an apology to drunken sailors,” Rep. Mark Walker, R-North Carolina, said to the Post.

Whether Republicans in Congress will unanimously back the proposal is unclear. Sen. Susan Collins, R-Maine, said the CHIP cut “concerns me greatly.” Senate Majority Leader Mitch McConnell, R-Kentucky, has privately appeared reluctant to go back on bipartisan deals made to pass the budget earlier this year.

“We are in discussions with the majority leader,” a Trump administration official said on a phone call with congressional staff, according to Politico. “We’re hopeful the Senate’s going to come our way but I would say it’s an ongoing conversation right now.”

Shoring up Republican support would be crucial as Democrats quickly criticized the cuts. Senate Minority Leader Chuck Schumer said in a statement the proposal would “tear apart” CHIP in an effort “to appease the most conservative special interests and feel better about blowing up the deficit to give the wealthiest few and biggest corporations huge tax breaks.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.